ArdelyxARDX
About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Employees: 395
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
27% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 62
21% more call options, than puts
Call options by funds: $7.48M | Put options by funds: $6.18M
0.63% more ownership
Funds ownership: 69.05% [Q1] → 69.68% (+0.63%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
9% less funds holding
Funds holding: 220 [Q1] → 201 (-19) [Q2]
19% less capital invested
Capital invested by funds: $808M [Q1] → $653M (-$155M) [Q2]
33% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 43
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Piper Sandler Christopher Raymond | 47%upside $9 | Neutral Maintained | 6 Aug 2025 |
Wedbush Laura Chico | 129%upside $14 | Outperform Maintained | 5 Aug 2025 |
Raymond James Ryan Deschner | 96%upside $12 | Outperform Maintained | 5 Aug 2025 |
HC Wainwright & Co. Matthew Caufield | 63%upside $10 | Buy Assumed | 18 Jun 2025 |
Financial journalist opinion
Based on 9 articles about ARDX published over the past 30 days
